WallStSmart

Concord Medical Services Holdings (CCM)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 14181% more annual revenue ($65.77B vs $460.51M). MRK leads profitability with a 13.6% profit margin vs -20.2%. CCM appears more attractively valued with a PEG of 0.57. MRK earns a higher WallStSmart Score of 50/100 (D+).

CCM

Hold

43

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 7.7Quality: 5.5
Piotroski: 6/9Altman Z: -0.95

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCMUndervalued (+68.0%)

Margin of Safety

+68.0%

Fair Value

$11.95

Current Price

$4.78

$7.17 discount

UndervaluedFair: $11.95Overvalued
MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCM3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
57.4%10/10

Revenue surging 57.4% year-over-year

Debt/EquityHealth
-1.7310/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.578/10

Growing faster than its price suggests

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

CCM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.19M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-21.9%2/10

ROE of -21.9% — below average capital efficiency

Free Cash FlowQuality
$-293.16M2/10

Negative free cash flow — burning cash

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CCM

The strongest argument for CCM centers on Revenue Growth, Debt/Equity, PEG Ratio. Revenue growth of 57.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : CCM

The primary concerns for CCM are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

CCM profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.20 — expect wider price swings.

CCM is growing revenue faster at 57.4% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 43/100). CCM offers better value entry with a 68.0% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Concord Medical Services Holdings

HEALTHCARE · MEDICAL CARE FACILITIES · China

Concord Medical Services Holdings Limited, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?